Literature DB >> 27627603

The impact of ovarian stimulation on the outcome of intrauterine insemination treatment: an analysis of 8893 cycles.

Jinyong Liu1, Tin-Chiu Li2, Jing Wang1, Wei Wang1, Zhen Hou1, Jiayin Liu3.   

Abstract

OBJECTIVE: To evaluate the impact of ovarian stimulation on the outcome of intrauterine insemination (IUI).
DESIGN: Retrospective analysis.
SETTING: A single university-based centre. POPULATION: A total of 5109 couples with 8893 cycles.
METHODS: The outcome of IUI with different protocols for ovarian stimulation was examined. MAIN OUTCOME MEASURES: The live birth rate (LBR), twin pregnancy rate and ovarian hyperstimulation syndrome (OHSS).
RESULTS: In ovulatory women without ovarian stimulation, the LBR was 7.6%. Stimulation with clomifene citrate (CC), letrozole (LE), human menopausal gonadotrophin (HMG), CC or LE combined with HMG achieved LBRs of 6.1, 5, 7.9, 8 and 12.2%, respectively. LE combined with HMG achieved a significantly improved LBR compared with no stimulation. HMG stimulation was associated with a higher rate of twins (7.4%) than no stimulation (0%, P < 0.01). In ovulatory women, the LBR appeared lower in CC and LE compared with no stimulation (P > 0.05). In anovulatory women, ovarian stimulation with CC, LE, HMG, CC or LE combined with HMG achieved LBRs of 11.3, 5.1, 11.8, 12.6 and 13.6%, respectively. No significant difference was observed. There were no triplet pregnancies or OHSS in stimulated cycles.
CONCLUSIONS: In ovulatory women, ovarian stimulation with LE combined with HMG achieved a significantly improved live birth rate. HMG stimulation resulted in a high risk for twins. TWEETABLE ABSTRACT: In ovulatory women, ovarian stimulation with letrozole and HMG resulted in a significantly improved LBR.
© 2016 Royal College of Obstetricians and Gynaecologists.

Entities:  

Keywords:  Clomifene citrate; human menopausal gonadotrophin; intrauterine insemination; letrozole; live birth rate; ovarian stimulation; 卵巢促排卵; 宫腔内人工授精; 尿促性素; 来曲唑; 活产率

Mesh:

Substances:

Year:  2016        PMID: 27627603     DOI: 10.1111/1471-0528.14020

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  6 in total

Review 1.  Evaluation of the Risk of Birth Defects Related to the Use of Assisted Reproductive Technology: An Updated Systematic Review.

Authors:  Dawid Serafin; Beniamin Oskar Grabarek; Dariusz Boroń; Andrzej Madej; Wojciech Cnota; Bartosz Czuba
Journal:  Int J Environ Res Public Health       Date:  2022-04-18       Impact factor: 4.614

2.  Effects of letrozole combined with human menopausal gonadotrophin in ovarian stimulation for intrauterine insemination cycles.

Authors:  Xiaoying Yu; Zhiwen Cao; Wenwen Hou; Weihua Hu; Guijun Yan
Journal:  Ann Transl Med       Date:  2019-12

3.  The effect of slow release insemination on pregnancy rates: report of two randomized controlled pilot studies and meta-analysis.

Authors:  Julian Marschalek; Maximilian Franz; Yael Gonen; Jan-Steffen Kruessel; Amnon Weichselbaum; Lorenz Kuessel; Marie-Louise Trofaier; Johannes Ott
Journal:  Arch Gynecol Obstet       Date:  2017-02-14       Impact factor: 2.344

4.  Risk Assessment of the Increased Occurrence of Congenital Cardiac and Non-Cardiac Defects in Fetuses with a Normal Karyotype after Assisted Fertilization in Comparison to Natural Fertilization Based on Ultrasound Diagnostics.

Authors:  Dawid Serafin; Beniamin Oskar Grabarek; Dariusz Boroń; Andrzej Madej; Bartosz Czuba
Journal:  J Clin Med       Date:  2021-11-29       Impact factor: 4.241

5.  The İmpact of Gonadotropin Type on Controlled Ovarian Stimulation and İntrauterine İnsemination Cycle Outcomes.

Authors:  Ozge Senem Yucel Cicek; Merve Demir
Journal:  J Hum Reprod Sci       Date:  2022-03-31

6.  Association between endometrial thickness and neonatal outcomes in intrauterine insemination cycles: a retrospective analysis of 1,016 live-born singletons.

Authors:  Jialyu Huang; Jiaying Lin; Xuefeng Lu; Hongyuan Gao; Ning Song; Renfei Cai; Yanping Kuang
Journal:  Reprod Biol Endocrinol       Date:  2020-05-14       Impact factor: 5.211

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.